Effects of Integrase Inhibitor–Based ART on the NLRP3 Inflammasome Among ART-Naïve People With HIV. (29th September 2020)

• Record Type: Journal Article
• Authors: Toribio, Mabel; Burdo, Tricia H; Fulda, Evelynne S; Cetlin, Madeline; Chu, Sarah M; Feldpausch, Meghan N; Robbins, Gregory K; Neilan, Tomas G; Melbourne, Kathleen; Grinspoon, Steven K; Zanni, Markella V
• Is Part Of: Open forum infectious diseases. Volume 7:Number 10(2020)
• Publication Date: 2020-09-29
• Subjects: atherosclerosis -- cardiovascular disease -- caspase-1 -- HIV -- NLRP3 inflammasome -- pyroptosis; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofaa459
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: The NOD-like receptor protein family pyrin domain containing 3 (NLRP3) inflammasome, activated in the setting of HIV, contributes to pro-atherogenic inflammation. Among antriretroviral therapy–naïve people with HIV (vs controls), levels of caspase-1—a key component of the NLRP3 inflammasome—were significantly increased. Six months of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate significantly decreased caspase-1 levels in association with CD4+/CD8+ ratio recovery. Trial registration . ClinicalTrials.gov NCT 01766726.